- Home
- ENTX vs JMM Comparison
ENTX vs JMM Comparison
Compare ENTX & JMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- JMM
- Stock Information
- Founded
- ENTX 2010
- JMM 1988
- Country
- ENTX Israel
- JMM United States
- Employees
- ENTX N/A
- JMM N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- JMM Trusts Except Educational Religious and Charitable
- Sector
- ENTX Health Care
- JMM Finance
- Exchange
- ENTX Nasdaq
- JMM Nasdaq
- Market Cap
- ENTX 69.6M
- JMM 58.2M
- IPO Year
- ENTX 2018
- JMM N/A
- Fundamental
- Price
- ENTX $1.67
- JMM $6.20
- Analyst Decision
- ENTX Strong Buy
- JMM
- Analyst Count
- ENTX 1
- JMM 0
- Target Price
- ENTX $10.00
- JMM N/A
- AVG Volume (30 Days)
- ENTX 46.7K
- JMM 16.1K
- Earning Date
- ENTX 03-28-2025
- JMM 01-01-0001
- Dividend Yield
- ENTX N/A
- JMM 5.44%
- EPS Growth
- ENTX N/A
- JMM N/A
- EPS
- ENTX N/A
- JMM N/A
- Revenue
- ENTX $181,000.00
- JMM N/A
- Revenue This Year
- ENTX N/A
- JMM N/A
- Revenue Next Year
- ENTX N/A
- JMM N/A
- P/E Ratio
- ENTX N/A
- JMM N/A
- Revenue Growth
- ENTX N/A
- JMM N/A
- 52 Week Low
- ENTX $1.41
- JMM $5.29
- 52 Week High
- ENTX $3.35
- JMM $6.10
- Technical
- Relative Strength Index (RSI)
- ENTX 32.36
- JMM 50.95
- Support Level
- ENTX $1.85
- JMM $6.15
- Resistance Level
- ENTX $2.02
- JMM $6.45
- Average True Range (ATR)
- ENTX 0.11
- JMM 0.07
- MACD
- ENTX -0.01
- JMM 0.00
- Stochastic Oscillator
- ENTX 10.87
- JMM 32.43
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.